In our previous study, we have shown that vector pBV22210 containing a chloramphenicol resistance and a cryptic plasmid pMB1 from Bifidobacterium longum strain could stably replicate and did not significantly affect the biological characteristics of B. longum. In this study, B. longum was transfected by electroporation with pBV22210 encoding the extracellular domain of TRAIL (B. longum-pBV22210-TRAIL) and its carbohydrate fermentation and growth curve were determined, and its location and inhibitory effect on tumor xenografts in mice were also examined. The results further proved that gene transfection did not change the main biochemical characteristics of B. longum. The results also showed that B. longum-pBV22210-TRAIL resulted in selective location in tumors and exhibited a definite antitumor effect on S180 osteosarcoma. In addition, when a low dosage of Adriamycin (5 mg kg À1 ) or B. longum-pBV22210-endostatin was combined, the antitumor effect was significantly enhanced. The successful inhibition of S180 tumor growth suggested a stable vector in B. longum for transporting anticancer genes combined with low-dose chemotherapeutic drugs or other target genes is a promising approach in cancer gene therapy.
Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of tumor necrosis factor superfamily.
1,2 TRAIL triggers apoptosis through binding to its membrane receptors (DR4 and DR5) and activating caspase-8 in majority of tumor cells but not in normal cells. [3] [4] [5] [6] [7] [8] Recombinant soluble human TRAIL is thought to be a candidate for cancer therapy because of its potent antitumor effects without toxicity in normal cell and/or tissue in vitro and in vivo. [9] [10] [11] In addition, combination treatment with TRAIL and chemotherapy showed a synergistic effect in human cancer cell lines and tumor xenograft models, even in drug-resistant cells and tumors. [12] [13] [14] Not only as probiotics but also as anaerobe, Bifidobacterium longum can be used as a useful host cell for heterologous protein production due to the following reasons: (1) protection of the intestinal mucosa and suppression of the permanent planting of detrimental gut microorganisms; 15, 16 (2) induction of the releasing of endogenous mediator with immunological activity and enhancement of immunity of host 17 and (3) inhibition of tumor growth by suppressing cancer related genes, selective localization and proliferation within hypoxic tumors. [18] [19] [20] [21] [22] However, the fact that exogenous plasmids cannot replicate stably in Bifidobacterium limits the application of Bifidobacterium in cancer gene therapy. Though some Bifidobacterium-Escherichia coli shuttle vectors have been constructed in recent years, only some of them expressed foreign genes successfully. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In our previous studies, we developed a shuttle vector (pBV22210), which could replicate stably and expressed recombinant human endostatin in both E. coli and B. longum. B. longum transfected with pBV22210-endostatin showed a clear inhibitory effect on the growth of mouse solid liver tumor in vivo. 30 Taking advantage of the stability of pBV22210 in B. longum, the tumor sitespecific localization of B. longum and the induction of apoptosis in cancer cells by TRAIL, we reported here the cloning of the extracellular domain of TRAIL (amino acid 114-281) to the downstream of His-tag of pBV22210, the transfection of B. longum, and the characterization of the transfectants. Antitumor activity of B. longumpBV22210-TRAIL combining with chemotherapeutic drugs or B. longum-pBV22210-endostatin in xenograft models of S180 osteosarcoma was examined.
Materials and methods
Bacterial strains and plasmids E. coli strain DH5a, wild-type (WT) B. longum, B. longum-pBV22210-endostatin and plasmid pBV22210-endostatin were preserved in our laboratory. pET28a-TRAIL was a generous gift from Professor Yayi Hou at School of Medicine, Nanjing University.
Reagents and enzymes
Adriamycin (batch C60705) was obtained from Haizheng Pharmaceutical Enterprise (Taizhou, China), Cyclophosphamide (CTX; batch 06122921) was purchased from Jiangsu Hengrui Medicine Co. Ltd (Lianyungang, China). 2 Â Taq mix was purchased from Tiangen Biotech (Beijing, China), T4 DNA ligase and restriction endonucleases were purchased from Takara Bio (Dalian, China). Primers were synthesized by Shanghai Shenergy Biocolor BioScience and Technology Company (Shanghai, China).
Animals and tumors
Male Kunming mice (19 ± 2 g) were obtained from Qinglongshan Animal Center (Nanjing, China). The animals were maintained in a pathogen-free environment at a constant temperature and supplied with laboratory chow and water ad libitum on a 12-h dark/light cycle. S180 mouse osteosarcoma (mouse with hydroperitoneum) was purchased from Jiangsu Institute for Cancer Prevention and Cure (Nanjing, China). S180 cancer cells (1 Â 10 7 ) were injected subcutaneously in the right flank of each mouse to establish tumor models. Restriction endonuclease digestion of pBV22210-endostatin and TRAIL. pBV22210-endostatin and TRAIL were digested by EcoRI/BamHI and the restricted pBV22210 and TRAIL fragments were gel-purified before the ligation of the PCR products and pBV22210 at the EcoRI/BamHI site. The ligation solution was transferred into competent cells of DH5a and pBV22210-TRAIL was detected on LB agar plate with 10 mg ml À1 chloramphenicol ( Figure 1 ). 30 Electroporation Electrocompetent cells of B. longum were prepared according to Rossi et al. 34 Bacteria were resuspended in about 1/100 of the original culture volume of ice-cold 0.5 M sucrose plus 1 mM ammonium citrate (pH 6.0); 1.0 mg of purified pBV22210-TRAIL plasmid was added in bacteria suspension and incubated at 4 1C for 2-3 h. This mixture was added in a precooled sterile Gene Pulser disposable cuvette (interelectrode distance 0.2 cm; Bio-Rad, Hercules, CA). The pBV22210-TRAIL plasmids were transfected directly into B. longum by electroporation in a Bio-Rad Gene-Pulser apparatus at 25 mF and 2.5 kV with the pulse controller set at 200 O. Then the mixture was inoculated in TPY culture and anaerobically cultivated overnight at 37 1C. Overnight culture was diluted, plated on TPY agar plates and monoclones were Carbohydrate fermentation assay TPY broth supplemented with different carbon sources was used for the determination of carbohydrate fermentation, with bromocresol purple (0.04 g l
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À1
) as a pH indicator. 27 After anaerobic incubation in the medium at 37 1C for 8 days, B. longum-pBV22210-TRAIL and WT B. longum were detected by the color of indicator.
Growth assay and morphologic analysis
Overnight culture of B. longum-pBV22210-TRAIL in TPY medium was inoculated into fresh medium with and without 5 mg ml À1 chloramphenicol to an initial optical density value of 0.010 at 600 nm (OD 600). The cultures were grown under anaerobic conditions at 37 1C for 24 h and OD values were measured every hour. WT B. longum cells were used as a control.
B. longum-pBV22210-TRAIL and WT B. longum cells were cultured in TPY medium till they grew to a logarithmic phase, harvested and washed twice with 0.1 M PBS (pH 7.0) by centrifugation. After smeared and affixed on a slide, the cells were stained with Gramstain reagent following the instructions and examined under Â 1000 objective of a light microscope.
Examination of localization of B. longum-pBV22210-TRAIL in mice Seventy-two hours after hypodermic inoculation of S180 cells, the tumor-bearing mice were injected with the same dose of B. longum-pBV22210-TRAIL (1 Â 10 8 cells per mouse) via tail vein every 24 h for three times. At 1, 24, 48 and 96 h after the third injection, the tumor-bearing mice were killed (five per time), and tissue samples were obtained from the heart, liver, spleen, lung, kidney and tumor under aseptic conditions. Each tissue sample (0.1 g) was homogenized in 1 ml dextrose-saline solution (5% glucose in 0.9% NaCl). The homogenates were plated on the solid TPY medium (1.5% agar) and incubated anaerobically at 37 1C for 48 h. The number of colonies per dish was counted to determine the number of viable bacteria. Other tumor-bearing mice were injected with ampicillin (50 mg kg
À1
) at 96 h after the third injection of B. longum-pBV22210-TRAIL, the tumors were excised from mice at 24, 48 and 96 h after the injection of ampicillin. The homogenates of tumors were treated and incubated on the solid TPY medium (1.5% agar) as above.
Antitumor activity of B. longum-pBV22210-TRAIL and B. longum-pBV22210-endostatin The mice were weighted and divided into six groups randomly after hypodermic inoculation of S180 cells for 24 h. Mice as negative control were injected with dextrosesaline solution (0.4 ml per day, i.v., on days 1-7). Five treated groups were injected, respectively, with B. longumpBV22210-TRAIL (0.4 ml per day, i.v., on days 1-7), B. longum-pBV22210-endostatin (0.4 ml per day, i.v., on days 1-7), WT B. longum (0.4 ml per day, i.v., on days 1-7), combination of B. longum-pBV22210-TRAIL and B. longum-pBV22210-endostatin (0.2 ml þ 0.2 ml per day, i.v., on days 1-7), CTX (30 mg kg
, i.p., on days 4, 6, 8). All B. longum cells were washed and resuspended in dextrose-saline solution at a concentration of 2.5 Â 10 8 cells per ml before injection. CTX was suspended in dextrosesaline solution and 0.2 ml of the solution was injected each time per mice. The mice were killed on day 10, the tumors were excised and weighed. The volume of the tumors was calculated using the formula: tumor volume ¼ (width) 2 Â length Â 0.52. 36 The inhibition of tumor growth was determined by the following formula:
tumor weight=volume of control group À tumor weight=volume of treatment group tumor weight=volume of control group Â100%
Antitumor activity of B. longum-pBV22210-TRAIL combining chemotherapeutic drugs The mice were weighed and randomized into four groups (six per group) after hypodermic inoculation of S180 cells for 24 h. Mice as negative control were injected with dextrose-saline solution containing 5% glucose and 0.9% NaCl (0.4 ml per day, i.v., on days 1-7), and the mice in the three treated groups were injected with B. longumpBV22210-TRAIL (0.4 ml per day, i.v., on days 1-7), Adriamycin (5 mg kg
, i.p., on day 2), combination of B. longum-pBV22210-TRAIL (0.4 ml per day, i.v., on days 1-7) and Adriamycin (5 mg kg À1 , i.p., on day 2), respectively. All B. longum cells were washed three times and resuspended before injection as mentioned above. After injection intravenously via the tail vein on day 7, the mice were kept for an additional 3 days till they were killed on day 10. The weight and volume of the excised tumors and the inhibition of tumor growth were determined as described above.
Statistical analysis
The data were statistically analyzed using Student's t-test in both groups and ANOVA test in multiple groups. The comparisons among multiple groups were performed using Student-Newman-Keuls q-test. P values of o0.05 were considered to be significant.
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Identification of B. longum-pBV22210-TRAIL
The plasmids extracted from B. longum transfected with pBV22210-TRAIL were amplified by PCR and the results were shown in Figure 2. A band of about 500 bp was detected in B. longum-pBV22210-TRAIL but not in WT B. longum that served as a negative control.
Carbohydrate fermentation
The results demonstrated that the characteristics of B. longum-pBV22210-TRAIL were concordant to that of WT B. longum cells in carbohydrate fermentation except for three carbohydrates: salicin, mannose and melezitose (Table 1 ). B. longum-pBV22210-TRAIL cells fermented salicin and mannose but not melezitose, whereas WT B. longum cells showed contrary results.
Growth and morphological characteristics
The growth curve of B. longum-pBV22210-TRAIL and WT B. longum cells were similar in TPY medium without selective pressure whereas the lag phase of B. longumpBV22210-TRAIL in selective medium was statistically longer than that in nonselective medium as shown in Figure 3 . Both B. longum-pBV22210-TRAIL and WT B. longum cells in TPY medium without chloramphenicol grew to an exponential phase after 6 h and stationary phase (OD 600 ¼ 1.1) after 10 h of incubation. However, B. longum-pBV22210-TRAIL cells in TPY medium with chloramphenicol (5 mg ml À1 ) grew to an exponential phase after 15 h and stationary phase after 18 h of incubation. tissues decreased rapidly 24 h after injection indicated that transformed B. longum did not germinate in normal tissues. Interestingly, the number of transformed B. longum located in tumors decreased rapidly after the treatment of ampicillin; few viable bacilli were detected in tumors 96 h after the administration of ampicillin.
Localization and decolonization of
Effect of B. longum-pBV22210-TRAIL and B. longumpBV22210-endostatin on growth of S180 tumor xenografts We established a xenograft model to assess the efficacy of B. longum-pBV22210-TRAIL and B. longum-pBV22210-endostatin. The tumors excised from each group were shown in Figure 5a . 
Effect of B. longum-pBV22210-TRAIL and Adriamycin on growth of S180 tumor xenografts
To examine the activity of B. longum-pBV22210-TRAIL cells in vivo, we developed a xenograft model in which S180 cells were injected s.c. into Kunming mice. Tumors grew rapidly in dextrose-saline solution-treated mice and slower in treated groups, especially in the combination treatment group. The tumors excised from each group were shown in Figure 6a . Compared to dextrose-saline solution group, combination treatment with B. longum-pBV22210-TRAIL and low-dose Adriamycin markedly inhibited tumor growth by 70.0% (P ¼ 0.0009) as measured by weight and by 75.5% (P ¼ 0.0002) as measured by volume; B. longumpBV22210-TRAIL alone inhibited tumor growth by 56.0% (P ¼ 0.0026) by weight and by 59.2% (P ¼ 0.0013) by volume; low-dose Adriamycin alone by 39.5% (P ¼ 0.0222) by weight and by 34.2% (P ¼ 0.0671) by volume, respectively (Figures 6b and c) . Combination treatment enhanced tumor inhibition rate by 14.0% (P ¼ 0.052) and 20.5% (P ¼ 0.027) as measured by tumor weight and by 16.3% (P ¼ 0.099) and 41.3% (P ¼ 0.033) as measured by tumor volume, respectively, compared to either agents used alone. Therefore, combination of B. longum-pBV22210-TRAIL and Adriamycin showed a more effective inhibition in tumor growth than either B. longum-pBV22210-TRAIL alone or low-dose Adriamycin alone.
Discussion
Although the advantages of Bifidobacterium as a genedelivery vehicle have been confirmed for several decades, (2002) transfected WT B. longum with pBLES100-S-eCD to produce CD in hypoxic tumors and achieved tumor site-specific conversion of 5-FC to 5-FU that resulted in significant antitumor effect in rat bearing autochthonous mammary tumors not only by intratumoral injection but also by systemic administration of transfected B. longum. 26 Fu et al. 28 used transformed B. longum carrying shuttle vector pBV220 (Amp þ ) encoding human endostatin as a delivery system and succeeded in selective localization within solid tumors and inhibiting growth of liver tumor xenografts in mice. However, ampicillin is considered to be harmful to bacterial cytoderm synthesis after electroporation, Xu et al. 30 constructed a new vector pBV22210-endostatin combining a chloramphenicol resistance gene and a cryptic plasmid pMB1 from WT B. longum strain that made the transformed B. longum more stable, and the expressed recombinant protein from B. longumpBV22210-endostatin exhibited stronger suppression of tumor growth in xenografts models than that from B. longum-pBV220-endostatin in a previous study. Based on the previous work, we further constructed a new plasmid B. longum-pBV22210-TRAIL that encoded the extracellular domain of TRAIL ( Figure 2 ) and expressed recombinant human TRAIL in B. longum successfully (data not shown) in this study.
Maintenance of the inborn characteristics of B. longum is of great significance for retaining the physiological role of B. longum. Carbohydrate fermentation indicates the ability of transformed B. longum to use carbon source and it is considered to be an important basis to identify bacterium strain. The results showed that B. longumpBV22210-TRAIL differed from WT B. longum cells in carbohydrate fermentation in salicin, mannose and melezitose. The characteristics of two type B. longum in carbohydrate fermentation were essentially consistent as it was reported that the fermentation of L-arabinose, gluconate, inulin, lactose, D-mannose, methyl a-D-glucoside, ribose, salicin, trehalose or xylose was variable in B. longum. 38 Morphology and growth curve were two additional indexes that illustrate the main biochemical characteristics of transformed B. longum. Therefore, we further determined the morphology and growth curve to confirm that transfection of TRAIL did not alter the main biochemical characteristics. Our results indicated that B. longum-pBV22210-TRAIL exhibited similar properties in biochemical, growth and morphological characteristics (data not shown) as WT B. longum, and it was consistent with Xu et al.'s study. 30 WT B. longum and transformed B. longum could both specifically reach tumor tissue by circulation and grow in hypoxic solid tumors as reported by Yazawa K et al.
25
Our results were consistent with the observation by demonstrating the presence of the viable bacilli of transformed B. longum in several main organs of the treated mice. The relatively hypoxia region and abundance of nutrition in tumor offer the possibility of B. longum cells' colonization. However, the mechanism of B. longum's localization to the tumor tissue from the blood has not been illustrated. It is possible that thin vessel walls and wide intercellular space between endothelial cells in the special vascular structure of solid tumors contribute to high permeability of blood vessels, which may make the translocation of B. longum easier and quicker. As Bifidobacterium can be killed easily by antibiotics such as kanamycin, cefoperazone and penicillin in vitro as shown in our previous study, 30 we tested B. longum's sensitivity to ampicillin in a decolonization assay and found that the number of B. longum located in tumors decreased drastically after an injection of ampicillin following the treatment of B. longum-pBV22210-TRAIL. The result implicated that the expression of target gene could be controlled, and it is helpful for further application of B. longum.
The suppressive effect of B. longum-pBV22210-TRAIL on tumor growth was also determined in osteosarcoma xenograft models in vivo. As B. longum-pBV22210-endostatin was proved to have definite inhibitive effect on tumor growth in our previous study, 30 we examined the activity of combination of B. longum-pBV22210-TRAIL and B. longum-pBV22210-endostatin and assessed the synergistic effect of the combination treatment. We propose two possible mechanisms for the phenomenon: on one hand, endostatin as an angiogenesis inhibitor depressed the vascularization and reduced provision of nutrition in tumor growth; on the other hand, TRAIL induced apoptosis of tumor cells through binding to its receptors and activating related apoptosis pathways. Thus, tumor growth was significantly suppressed by the combination of TRAIL and endostatin. The tumor inhibition rate in combination group was 20% higher than that in B. longum-pBV22210-TRAIL or B. longumpBV22210-endostatin group when used alone. Furthermore, as many chemotherapeutic drugs have severe side effects, we chose low-dose Adriamycin to combine with TRAIL and determined their synergistic effect in tumor growth inhibition. Combination of B. longum-pBV22210-TRAIL and low-dose Adriamycin (5 mg kg À1 ) resulted in the higher inhibition of tumor growth. Similarly, the sequential treatment with chemotherapeutic drugs followed by TRAIL induced apoptosis in breast tumor cells and resulted in the inhibition of tumor growth and the improved survival rate of tumor-bearing nude mice. 39 Jin et al. 40 demonstrated that administration of TRAIL plus Taxol and Carboplatin led to suppression of tumor growth and improved survival significantly in both subcutaneous and orthotopic lung tumor xenograft models. The mechanism for chemotherapeutics enhancing TRAIL-induced apoptosis in tumor cells has not been completely elucidated. A recent study showed that treatment with subtoxic doses of silibinin in combination with TRAIL induced rapid apoptosis in TRAIL-resistant glioma cells through upregulating DR5 and downregulating the levels of the antiapoptotic proteins FLIP L , FLIP S and survivin. 41 After pretreated with cis-Diaminedichloroplatinum, Etoposide (VP-16), Adriamycin and vincristine, sensitization of TRAIL-and drug-resistant prostate carcinoma PC-3 cells to TRAIL-induced apoptosis was enhanced via inhibition of the transcription repressor Yin Yang 1 and upregulation of DR5 expression. 42 Other reports also indicated that antineoplastic agents were capable of upregulating levels of DRs (DR4 and DR5), [43] [44] [45] inducing (for example, Bax and Bak) or reducing (for example, Bc1-2 and Bcl-xL) proapoptotic Bcl-2 family members, 46, 47 changing the relative levels of RelA and c-Rel subunits of nuclear factor-kB. 48 Moreover, it has been shown that the synergistic effects of chemotherapeutic drugs and TRAIL on apoptosis occur through activation of downstream caspase-3, which can be activated by both mitochondria-dependent and -independent pathways. 39 Therefore, chemotherapy can sensitize tumor cells to TRAIL-induced apoptosis in part through death receptors upregulation, and in part through cross-talk between the intrinsic and extrinsic pathways. Combination of TRAIL with chemotherapy resulted in reversal of resistance to TRAIL-mediated apoptosis and enhancement of TRAIL's efficiency, however, sensitivity of human normal cells to such combinations is not well known. A recent study showed that TRAIL/cisplatin showed toxicity toward human primary hepatocytes and resting lymphocytes, both TRAIL/5-fluorouracil and TRAIL/cisplatin combinations are toxic toward PHA-IL2-activated lymphocytes. 49 These results suggest the importance to conduct cytotoxicity study of TRAIL/anticancer drug combinations in normal cells.
In summary, we have developed a strategy of combining TRAIL with antineoplastic agents or other genes (for example, endostatin) for the treatment of osteosarcoma by using B. longum as an effective delivery system. The combination treatment resulted in significant inhibition of tumor growth, comparing with TRAIL, chemotherapy or endostatin treatment alone. Our results support the potential of combination of chemotherapy and tumor therapeutic target genes to provide a novel, selective localization and apoptosis-based biological approach for advancing the treatment of cancer.
